| Date | Title | | | 03/05/10 | Rigel to Present at Cowen and Company Health Care Conference| SOUTH SAN FRANCISCO, Calif., March 5, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Cowen and Company 30th Annual Health Care Conferencein Boston, Massachusetts on Tuesday, March 9th at 3:45 p.m. EST.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website... |
|  | | 03/02/10 | Rigel Announces Fourth Quarter and Year End 2009 Financial Results| SOUTH SAN FRANCISCO, Calif., March 2, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2009.
For the fourth quarter of 2009, Rigel reported a net loss of $25.1 million, or $0.48 per share, compared to a net loss of $33.4 million, or $0.91 per share, in the fourth quarter of 2008. Weighted average shares outstanding for the fourth quarters of 2009 and 2008 were 51.8 million and 36.6 mil... |
| | | 02/16/10 | Rigel to Host Conference Call Today to Discuss Its Partnership With AstraZeneca on Fostamatinib Disodium (R788)| SOUTH SAN FRANCISCO, Calif., Feb 16, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to discuss its partnership with AstraZeneca for Rigel's late-stage investigational product, fostamatinib disodium (R788), for the treatment of rheumatoid arthritis and additional indications.
Conference Call and Webcast Information
To access t... |
| | | 02/16/10 | AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)| SOUTH SAN FRANCISCO, Calif., Feb 16, 2010 /PRNewswire via COMTEX/ -- AstraZeneca and Rigel Pharmaceuticals (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications. Fostamatinib disodium, which has completed a comprehensive phase 2 program, is the furthest developed oral Spleen Tyrosine Kinase (Syk) i... |
| | | 02/05/10 | Rigel to Present at BIO CEO & Investor Conference| SOUTH SAN FRANCISCO, Calif., Feb 05, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8th at 10:00 a.m. EST.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several min... |
| |
|
rigel in the news
